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Background: The incidence of venous thromboembolic disease (VTED) is estimated to be, on average, 1–2 cases
per 1,000 individuals per year worldwide. There are few data concerning the incidence rate (IR) of VTED in the
Argentinean population at large.
Our aim was to estimate the IR of VTED at the Italian Hospital Medical Care Program (IHMCP) in Buenos Aires, the
most populous city in Argentina.
Methods: This prospective cohort study evaluated all consecutive incident cases of pulmonary thromboembolism
(PTE) and deep vein thrombosis (DVT) confirmed in patients over the age of 17 who were members of the IHMCP
from June 2006 to May 2012. Any patient who had an initial confirmed VTED episode and was a member of the
IHMCP at the time of diagnosis was considered an incident case.
Results: There were 1,138 cases of VTED for 687,871 person-years of follow-up. The crude IR of VTED was 1.65 (95%
CI: 1.56 to 1.75) per 1,000 person-years. The highest IR was found in subjects >80 years old (5.92 per 1,000 person
years; 95% CI: 5.41 to 6.49).
The IRs adjusted to the population of the city of Buenos Aires were 0.90 (95% CI: 0.84 to 0.95) for VTED, 0.71 (95%
CI: 0.66 to 0.76) for DVT, and 0.34 (95% CI: 0.31 to 0.37) for PTE.
Conclusions: VTED is a common health problem with a high IR in members of the IHMCP, especially the elderly.
This is the first paper to report prospectively the cumulative incidence of VTED in Latin America.
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Venous thromboembolic disease (VTED) is the most
common preventable cause of death among hospital pa-
tients [1]. While VTED can affect patients of any age, it
is reported that its frequency increases in older individ-
uals [2]. The most common manifestations of VTED in-
clude pulmonary thromboembolism (PTE) and deep
vein thrombosis (DVT) of the lower limbs [1,3-6].* Correspondence: fernando.vazquez@hospitalitaliano.org.ar
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reproduction in any medium, provided the orPresentation signs and symptoms of VTED are unspecific
and, when untreated, may lead to fatal PTE [7], pulmonary
hypertension, and postphlebitic syndrome. [1,3-6,8,9]. The
most common risk factors for the development of VTED
are neoplasms, recent surgery, and hospitalisation for
medical reasons [10-12].
The incidence rate for the initial episode of VTED is
between 0.71 and 1.17 cases per 1,000 persons of the
Caucasian population [2,13-19]. The incidence variability
depends on the data source (detection through surveys
or via various diagnostic studies), the record type, symp-
tomatic or asymptomatic events, the inclusion of only
primary events or also recurrences, and study designl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Comparison of the demographics of the city of
Buenos Aires and the IHMCP based on the 2010
Argentina census
Age group City of Buenos Aires IHMCP data
n % n %
0 - 14 years 472,511 16.3 21,808 14.3
15 - 24 years 395,806 13.7 13,725 9
25 - 34 years 495,663 17.2 21,087 13.8
35 - 44 years 396,202 13.7 17,975 11.8
45 - 54 years 342,647 11.9 16,303 10.7
55 - 64 years 313,251 10.8 20,569 13.5
65 years and older 474,071 16.4 40,964 26.5
Abbreviations: IHMCP italian hospital medical care program, N number, % percentage.
Table 2 Criteria for diagnosis of VTED, DVT or PTE
Criteria for diagnosis
VTED DVT and/or PTE
DVT Confirmed with a Doppler ultrasound or angiography of the
veins of the lower and/or upper limbs.
PTE Positive 64-slice computed tomography (CT) angiogram (with a
filling defect in the main pulmonary artery, lobar, segmental, or
subsegmental branches), a high- or intermediate-probability
ventilation-perfusion scintigraphy (associated with high clinical
probability), and/or pulmonary angiography with evidence of a
thrombus in the pulmonary artery or in the lower pulmonary
arterial branch.
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have demonstrated incidence diversity in relation to
race, with increased incidence rates in the Caucasian
and African-American populations compared to His-
panic and Asian populations in the United States [19].
However, there are few data in Argentina and Latin
America about the epidemiology of VTED [20,21] and
this is the first paper reporting prospectively the inci-
dence of VTED, DVT, and PTE in a population of
Argentina. It is important to know the local epidemi-
ology of this disease, as it can greatly impact the morbid-
ity and mortality of patients. Thus, our goal was to
estimate the incidence rate (IR) of VTED within the
medical care program of the Italian Hospital of Buenos
Aires, the most populous city in Argentina, using pro-
spective symptomatic VTED data.
Methods
Population
A prospective cohort study was designed to evaluate all
adult members of the Italian Hospital Medical Care Pro-
gram (IHMCP) from June 1, 2006 to May 31, 2012. The
Italian Hospital of Buenos Aires (IHBA) is a general ter-
tiary level hospital offering comprehensive medical services
to a population of 145,000 beneficiaries of the IHMCP, a
prepaid health maintenance organisation (HMO) of the
city of Buenos Aires in Argentina.
All medical care interventions for the beneficiaries are
registered centrally in a computerised data repository, with
only one electronic health record (EHR) per person. Med-
ical care of all beneficiaries is carried out exclusively in the
IHBA health system, which includes two hospitals—one of
them highly specialised—with a total of 679 hospital beds.
Both hospitals are located in the city of Buenos Aires and
receive approximately 42,300 admissions annually. Ambu-
latory care is provided at these hospitals as well as 19
peripheral centres, which together receive more than
2.56 million outpatient visits per year [22].
On the other hand, according to the 2010 Argentinean
National Census, the autonomous city of Buenos Aires has a
population of 2,890,151 residents, of which 30% are under
the age of 25 and 21.7% are over 60 years of age [23].
According to the 2010 Census demographics, the population
distribution of patients included in the IHMCP is similar to
that of Buenos Aires in regards to age and sex (Table 1).
The study was done in compliance with the Helsinki
Declaration and was approved by the Ethics Committee
of HIBA (protocol N° 1877). Consent: Oral informed
consent was obtained from the patient for this study, as
is required in Argentina for observational designs.
Case detection
Since 2006, the IHBA has collected VTED cases in a prospect-
ive registry (the Institutional Registry of ThromboembolicDisease, IRTD [24]) that includes all consecutive patients
older than 17 years with suspected PTE and/or confirmed
PTE and DVT who were diagnosed in any hospital depart-
ment, including outpatient clinics, inpatient general wards
for all specialties (medical and surgical), and critical care
areas.
Possible VTED cases are captured for the IRTD
using a computerised alert that is generated whenever
the physician requests the following studies for an
adult patient: computed pulmonary angiography and
tomography, ventilation-perfusion scintigraphy, venous
Doppler ultrasound of the lower and/or upper limbs,
or angiography of the lungs and/or veins of the lower
and/or upper limbs. From the possible VTED cases in-
cluded in the IRTD during the 2006–2012 period, a
prospective review of the EHRs was performed to con-
firm the presence of PTE and/or DVT. The criteria for
diagnosis of VTED, DVT or PTE is presented in
Table 2 [25-30].
In this study, a case was considered incident if a pa-
tient had a confirmed first episode of VTED, PTE, and/
or DVT and if the same patient was enrolled in the
IHMCP at the time of diagnosis. A second episode of
VTED, PTE and/or DVT in a patient was not considered
incident.
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The IR was calculated for patients included in the
IHMCP according to the number of incident cases of an
initial VTED episode per 1,000 person-years. It was as-
sumed that the number of new cases of VTED, DVT, or
PTE corresponded to the numerator of the incidence
rate and that the denominator corresponded to the
number of person-years at risk. The rates were adjusted
by direct standardisation to the age and sex distribution
of the populations of Argentina and Buenos Aires
according to the 2010 Census [23], as well as in relation
to the European standard population and Segi’s world
standard population [31]. In addition, the specific IRs by
age and gender were evaluated. The incidence rates are
expressed per 1,000 person-years, with 95% confidence
intervals (95% CI), for the entire period. IRs are com-
puted from the study data, and the cumulative incidence
is estimated from the following formula using cumula-
tive incidence as a function of t (time in years) and
lambda (the IR): Cumulative Incidence (t) = 1 - exp
(−lambda * t) [32].
Results
During the study period, there were 1,138 patients with
an initial confirmed VTED episode, 169 were excluded
for a second episode of VTED, PTE and/or DVT. In
addition, during this 6-year period, the entire cohort of
IHMCP beneficiaries was followed and contributed a
total of 687,871.138 person-years. Of the total number
of VTED cases, 896 (78.80%) had DVT, 440 (38.66%)
had PTE, and 199 (17.48%) had both PTE and DVT. Fe-
males accounted for 62.56% (712) of VTED cases,
61.38% (550) of DVT cases, and 65% (286) of PTE cases.
The distribution of the risk factors in the study popula-
tion were: history of cancer 39% (414/1138), pregnancy
status 23% (7/31 women of childbearing potential), inpa-
tients 33% (373/1138) and surgery 27% (310/1138).
The crude IRs per 1,000 person-years was 1.65 for
VTED (95% CI: 1.56 to 1.75), 1.30 for DVT (95% CI:
1.22 to 1.39), and 0.64 for PTE (95% CI: 0.58 to 0.70)
(Table 3 and Figure 1).Table 3 Crude global IRs adjusted for Argentina, Buenos Aire
Person-years
at risk














(n = 440) (95% CI 0.58 – 0.70) (95% CI 0.20 – 0.25)
Incidence rates are expressed per 1,000 person-years. Abbreviations: IR incidence ra
n number, PTE pulmonary thromboembolism, DVT deep vein thrombosis.The sex-specific IRs per 1,000 person-years for VTED
was 1.72 (95% CI: 1.60 to 1.85) in the female group and
1.56 (95% CI: 1.42 to 1.71) in the male group; for DVT,
the IRs were 1.33 (95% CI: 1.22 to 1.44) in the female
group and 1.26 (95% CI: 0.13 to 1.40) in the male group;
for PTE, the IRs were 0.69 (95% CI: 0.61 to 0.77) in the
female group and 0.56 (95% CI: 0.48 to 0.66) in the male
group. The female/male IR ratios were 1.1 for VTED
(95% CI: 0.98 to 1.25), 1.05 for DVT (95% CI: 0.92 to
1.20), and 1.23 for PTE (95% CI: 1.01 to 1.50).
For cases of VTED, DVT, and PTE, stratifying the ana-
lysis by age did not identify cases among patients be-
tween 17 and 20 years of age; however, the specific rates
increased with age in patients belonging to the group
under study. As a result, the lowest specific IRs were
found in the group of patients between 21 and 30 years
of age, with values of 0.14 for VTED (95% CI: 0.08 to
0.25), 0.12 for DVT (95% CI: 0.06-0.22), and 0.03 for
PTE (95% CI: 0.01-0.11). In contrast, the group of sub-
jects over 80 years of age had the highest specific IRs,
with values of 5.93 for VTED (95% CI: 5.41 to 6.50),
4.62 for DVT (95% CI: 4.16 to 5.12), and 2.25 for PTE
(95% CI: 1.94 to 2.61) per 1,000 person-years (see
Figure 1).
The IRs of VTED, DVT, and PTE adjusted for the
population of Buenos Aires were 0.90 (95% CI: 0.84 to
0.95), 0.71 (95% CI: 0.66 to 0.76), and 0.34 (95% CI: 0.31
to 0.37) per 1,000 person-years, respectively. The IRs ad-
justed for the populations of Argentina, Buenos Aires,
Europe, and Segi’s world standards are shown in Table 3.
The cumulative incidence rates in the follow-up period
were 1.65 cases per 1,000 persons for VTED (95% CI:
1.47 to 1.85), 1.28 cases per 1,000 persons for DVT (95%
CI: 1.13 to 1.46), and 0.64 cases per 1,000 persons for
PTE (95% CI: 0.53 to 0.77).
Discussion
The results of this study show that the incidence rate
(IR) of symptomatic VTED in a medical care program of
the Italian Hospital of Buenos Aires, remains a major




Adjusted for Europe Adjusted for Segi’s
world standard
0.90 0.65 0.45
(95% CI 0.84 – 0.95) (95% CI 0.60 – 0.69) (95% CI 0.41 – 0.48)
0.71 0.52 0.36
(95% CI 0.66 – 0.76) (95% CI 0.48 – 0.56) (95% CI 0.33 – 0.39)
0.34 0.25 0.17
(95% CI 0.31 – 0.37) (95% CI 0.22 – 0.27) (95% CI 0.15 – 0.19)
te, VTED venous thromboembolic disease, 95% CI confidence interval of 95%,
Figure 1 Cude IRs of VTED, DVT, and PTE by age group for the 6cyear period from 2006 to 2012.
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few data in Argentina and Latin America about the epi-
demiology of VTED [20,21] and to our knowledge this is
the first paper reporting prospectively the incidence of
VTED in a population of Argentina.
Although several studies have reported the incidence
of VTED in various populations [2,13,15,16], many re-
ports included annual cumulative incidence values and
not IRs. As these indicators are not equivalent, we have
also reported annual cumulative incidence values to
compare our findings to those of previously published
studies [32].
The cumulative incidence of VTED in our study was
higher than the corresponding value reported in the
study of Silverstein et al. [2], as these authors detected
an average age- and gender-adjusted annual incidence
rate of 1.17 VTED cases per 1,000 persons in Olmsted
County, Minnesota, USA. This difference could be
explained by the variable clinical manifestations of the
disease, the degree of certainty in the diagnosis of VTED
according to the methods used to confirm the diagnosis
(the 64-slice CT angiogram was not yet available be-
tween 1966 and 1990), and the study design (in contrast
to the present study, the Silverstein Study was a retro-
spective study).
The progression of the specific IR with age was highly
related to the aging of the population under study. In
our study, we did not find cases of VTED in the group
aged 17 to 20 years, and the study by Silverstein et al.
reported only 4 cases in children younger than 15 years
of age after a 25-year follow-up period. Nevertheless,
both studies observed that the cumulative incidence was
highest in individuals over 80 years of age.
The average annual incidence of VTED reported by
Anderson et al. [13] was 1.07 per 1,000 persons in Wor-
cester, Massachusetts, which was also lower than the
corresponding value found in the present study. This
difference may be due to the study design, as only inpa-
tients were included in this study [13]. Moreover, thelack of inclusion of outpatients, who were included in
the current study, may explain the differences in
reported IRs because the recorded events were more fre-
quent among outpatients than those admitted to the
hospital.
In men over 50 years of age, Hansson et al. [33]
reported an annual VTED IR of 3.87 cases per 1,000
person-years, which was far higher than that described
in the current report. The reason for this discrepancy
may be explained by the older mean age of the subjects
in the Hansson study, as old age is a major risk factor
for VTED. Furthermore, the inclusion of autopsies tends
to overestimate the incidence due to asymptomatic PTE
cases that would not have been diagnosed during patient
care.
Similar to Anderson and Silverstein, we found no con-
vincing differences between men and women with VTED
[2,13] except for women younger than 55 years old, in
which Silverstein et al. [2] reported a higher incidence,
possibly due to hormonal influence. For PTE, we found
a greater incidence among women, with a female/male
IR ratio of 1.23 (95% CI: 1.01 to 1.5). In contrast,
Hansson et al. [33] reported cases only in men (they ex-
cluded women from their study), and the study by White
et al. [19] reported no difference between genders. In our
study, the reason for our observed gender-related differ-
ence could be due to the higher proportion of women
compared to men in the over-80 age group; these patients
may be more vulnerable and at greater risk.
Our study shows that VTED is strongly related to age.
This finding is consistent with that of White et al. [19],
who demonstrated a link between the incidence of
VTED and increasing age, with an exponential increase
in the annual cumulative incidence from 0.05 cases per
1,000 persons in children under 15 years of age to more
than 5 cases per 1,000 persons in those aged 80 years
and above. Similarly, the studies by Silverstein and An-
derson [2,13] reported increased VTED IRs among older
patients. This observation may be related to differential
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tary lifestyle, cancer, and other comorbidities) as well as
a higher clinical suspicion for VTED among older
patients.
The VTED “IR” adjusted for the population of Buenos
Aires was 0.89 per 1,000 person-years (95% CI: 0.84-
0.95), which indicates that this disease is a major health
problem. The discrepancy with the crude IR of VTED in
the IHMCP arises because 40% of the hospital benefi-
ciaries in the studied population were over 55 years of
age, which is higher than the proportion of the Buenos
Aires city population for that age group (by approxi-
mately 12.8%). Similar findings were made for the IR of
VTED in Argentina, as the value of 0.60 (95% CI 0.56 to
0.64) was lower than the corresponding aforementioned
values.
Furthermore, these results are supported by data from
the 2010 census, which reported that 27.2% of the popu-
lation was aged 55 years or greater. This finding suggests
that advanced age is strongly related to VTED. Age- and
sex-adjusted IRs of DVT and PTE for the population of
Buenos Aires were 0.71 and 0.34, respectively, which are
also high and indicate a major health problem.
As shown in Table 3, it can be observed that all crude
rates are higher than all age standardized rates to several
populations, with a preserved relation between VTED,
DVT and PTE rates. This is explained by the differences
in age and gender distribution among the groups of
people selected. Thus, IHMCP has an aged population,
with higher proportion of subjects in older age strata
compared to Argentina, Buenos Aires, Europe, and Segi’s
world standard. Since there is no available data in Latin
America on incidence of thromboembolic disease in
general population, findings of this study could be cau-
tiously generalized to other places. However, potential
limitations to generalizability include aged distribution
of the population of IHMCP and that it was done in only
one private institution of Buenos Aires City. Therefore,
future studies in other places of Latin America would in-
crease the external validity of this study and improve the
knowledge of this disease in the region.
The numbers reported here accurately depict the med-
ical practice at the IHBA HMO. An adequate description
of the situation regarding cases of VTED at the local
level, both within our hospital and in the city of Buenos
Aires, is essential to understand the magnitude of the
problem being addressed and to identify the groups that
are most at risk so that appropriate prevention measures
can be implemented for the most vulnerable patients.
All detected cases corresponded to symptomatic pa-
tients who were included because of a clinically suspected
initial VTED event, and these cases were recorded in the
IRTD when the diagnosis of VTED was objectively dem-
onstrated using a validated method.A potential limitation of this study could be cases that
were not considered to be included due to methodo-
logical feasibility. In this sense, we did not include aut-
opsy findings of asymptomatic patients who died of
other causes according to the attending physician and
without symptoms of VTED, nor did this paper consider
cases in which the physician considered the diagnosis as
possible but did not confirm it due to the patient’s ter-
minal condition as well as patients that were not studied
for VTED (asymptomatic or without clinical suspicion
of the attending physician). Unlike the study of
Silverstein, the objective of this study was to describe
only symptomatic thromboembolic events related to
routine clinical practice. Other potential limitations arise
from the type of study design. As a dynamic cohort
study, it is possible to present a differential loss of follow
up bias from subjects that leave the cohort for unknown
reasons as well as an eventual variability in time expos-
ure that cannot be addressed estimating risk by the inci-
dence density.
Conclusion
VTED is a major health problem, especially among the
elderly. These findings have serious implications for
current clinical practice because of the expected increase
in the population age. To our knowledge, this is the first
paper to report prospectively the cumulative incidence
of VTED in Argentina and Latin America.
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